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1. Introduction
Successive generations of scientists and nephrologists have failed to prevent or cure Acute
Kidney Injury (AKI) and thousands every year die because of this. Recent innovations in
proteomics and genomics have brought hope and renewed interest in preventing this blight.
Motivated by high incidence and lack of effective treatments, researchers have focussed on
how to detect AKI early in the disease process so as to provide the maximum opportunity for
early intervention and positive outcomes. AKI Incidence is greatest in the intensive care, at
about 11-52% in larger studies (n>500) (Ahlstrom et al. (2006); Bagshaw et al. (2008); Cruz
et al. (2007)). Cardiac surgery and procedures involving radiocontrast pose smaller, but
significant, risk of AKI with an incidence of 3-15% depending on cohort (Harjai et al. (2008);
Lassnigg et al. (2008)). From 13 studies the mortality with AKI was 31.2% and was associated
with an increase in relative risk of death from 2.40 to 6.15 depending on AKI severity (Ricci
et al. (2008)). Stimulating much recent research has been the discovery of new kidney injury
biomarkers, some of which appear to have sufficient sensitivity and specificity to be clinically
useful.
This chapter will outline the history of the development of the concepts of clearance, acute
renal failure, and acute kidney injury. This history provides the context for the current
clearance based AKI diagnostic paradigm. The discovery of novel kidney injury biomarkers is
challenging that paradigm. We will discuss the nature of that challenge and the opportunity
it provides for development of early intervention treatments. All epidemiology, biomarker
studies and clinical trials rely on tools to quantify AKI and assess efficacy of diagnostic or
treatment efficacy. In section 3 we will discuss those tools before moving on to considering
how they may best be applied in practice (section 4).
2. From ARF to AKI
2.1 Clearance and the rise and fall of creatinine
While suppression of urine flow, ischuria renalis, was recognised as a fundamental
manifestation of renal disease from the 17th Century, clear metabolic manifestations of AKI
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were not documented until World War I in the German and World War II in the English
literature (see Eknoyan (2002); McGrath (1852)). The term “Acute Renal Failure” first
appeared in the literature in 1946 (Frank et al. (1946)), although it has been attributed to
Homer Smith (Eknoyan (2002)). In keeping with a recent change in nomenclature we shall
use the term “Acute Kidney Injury” (AKI) unless we are specifically referring to an historic
use of ARF.
The historical development of clearance techniques and the relationship to glomerular
filtration rate (GFR) are discussed by Berliner in his tribute to the great renal physiologist
Homer Smith (Berliner (1995)). The term clearance was introduce in 1928 with reference to
urea and to clearance of a defined volume of plasma in unit time (Moller et al. (1928)). The idea
of creatinine clearance as a measure of glomerular filtration rate (GFR) was beautifully first
demonstrated by Rehberg in experiments on himself (Rehberg (1926)). These also highlighted
how variations in serum creatinine could be induced by diet: Rehberg ingested different
quantities of creatinine to vary his serum creatinine. The utility of clearance as a technique was
further established in the laboratory of Homer Smith, especially with para-amminohippuric
acid clearance, a measure of secretion and renal blood flow (Smith et al. (1945)).
Creatinine is formed non-enzymatically from creatine in muscle, has a molecular weight
of 113.12 Da, is freely filtered at the glomerulus and completely cleared by renal excretion
when renal function is normal. The proximal tubules secrete creatinine, which accounts for
10 to 20% of the excreted load, and results in overestimation of GFR when measured by
creatinine clearance (Perrone et al. (1992); Shemesh et al. (1985)). The contribution of tubular
creatinine secretion to clearance, is increased when GFR is reduced and may reach 50%, but is
highly variable amongst individuals (Perrone et al. (1992)). In contrast, the tubules reabsorb
creatinine in some clinical settings such as decompensated heart failure and uncontrolled
diabetes (Levinsky & Berliner (1959); Perrone et al. (1992)).
With creatinine clearance firmly established as a reasonable approximation to GFR, the next
step was to estimate creatinine clearance based on the reciprocal relationship with plasma
creatinine. This was popularized by the Cockroft-Gault equation which was derived by, firstly,
a regression to estimate creatinine excretion/kg body weight according to age in hospitalised
male patients; then clearance was calculated by multiplying by weight and dividing by the
serum creatinine (Cockcroft & Gault (1976)). An untested 15% reduction for female gender
was included, based on the observation that, on average, females had less fat and muscle
mass than males (Cockcroft & Gault (1976)). This formula has been widely replaced by other
estimates of GFR (eGFR), most notably by the Modification of Diet in Renal Disease (MDRD)
equation originally developed in a population of CKD patients (Levey et al. (1999)).
Many alternative algorithms for creatinine-based eGFR have been developed, including those
regularly in use for children; these equations are more accurate and precise than estimates
from measurement of creatinine alone (KDOQI Clinical Practice Guidelines for Chronic Kidney
Disease: Evaluation, Classification, and Stratification (2002)). The various iterations of the MDRD
equation rely on plasma creatinine plus several other variables, including gender and race,
and originally albumin and urea (as blood urea nitrogen) concentrations, but excluding mass
although they do incorporate body surface area via the units; the latest version is more
accurate than the MDRD equation for patients with GFR>60 ml/min (Levey et al. (2009)) but
caveats remain (Rule (2010)) and drug dosing tends to be based on Cockroft-Gault (Ryzner
(2010)).
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Classical measurement of clearance with timed urine collection is cumbersome, so logically,
the surrogate of clearance, the serum creatinine (actually measured in plasma), is usually the
sole measure used to define renal status including development of AKI. However, serum
creatinine increases slowly in response to a single step alteration in GFR. Serum creatinine
has a half-life of approximately 4 hours when GFR is normal and 77 hours when GFR is
reduced to 5% (Chiou & Hsu (1975); see section 3.1). As 3 to 5 half-lives are required
after any change in GFR to obtain a new steady-state estimate, a reliable GFR based on
the serum creatinine will require at least 12 hrs after even a minimal change in GFR. The
current consensus definition (RIFLE: Risk, Injury, Failure, Loss, End-stage) of AKI requires
at least a 33% decline in GFR, but a 25% reduction is traditionally accepted for diagnosis of
contrast-induced AKI) (Bagshaw et al. (2008); Endre et al. (1989); Pickering & Endre (2009a)).
Thus a new steady-state creatinine-based estimate of GFR will take from 24 to 72 hours.
Obviously, the extent of increase in creatinine, which is determined by the extent of initial
decrease in GFR and creatinine production, may allow diagnosis of AKI prior to the time
needed to reach steady-state. However, the limited precision of creatinine measurement
and the extent of intra-patient variation mean that a minimum 10% change in creatinine
has traditionally been required by clinicians to demonstrate measurably significant change.
An increase in serum creatinine has also been used as a major trigger for intervention (renal
replacement therapy, RRT) in both AKI and chronic kidney disease (Gibney et al. (2008)).
The recognised imprecision in determining change in GFR led to removal of GFR from the
new Acute Kidney Injury Network (AKIN) consensus classification of AKI so that an absolute
or percentage increase in creatinine alone or in combination with oliguria has become the
new consensus definition of AKI (Mehta et al. (2007)). Thus, despite many limitations, such
as dependence on muscle mass, diet etc (Perrone et al. (1992)), serum creatinine became
the accepted shorthand for estimating GFR and significant change in creatinine became the
definition of AKI and marker of AKI severity.
Since there is an inverse relationship between serum creatinine and GFR, it is easy to
forget that a small increase in serum creatinine represents a substantial decline in GFR.
Consequently, prior to the now widespread reporting of eGFR estimated from creatinine,
clinicians often ignored small increases in creatinine, and characterised these as “mild”
or “moderate” increases. Combined with the uncertainty associated with the precision of
measurement, years of ignoring such small increases in creatinine have impaired insight into
how AKI is triggered. Even if an increase is observed, the delay required for diagnosis creates
uncertainty regarding the timing of the renal insult leading to AKI. This represents a lost
opportunity to investigate and identify the underlying pathophysiology of AKI in humans.
Even mild grades of severity of AKI and transient (less than 24 hour increases in creatinine)
are associated with increased hospital mortality (Chertow et al. (2005); Uchino et al. (2010;
2006)).
Inevitably, much of our interpretation of the pathophysiology of AKI is based on an animal
model; the classical model utilises temporary cessation of renal blood flow to induce injury,
usually through bilateral renal artery clamping. While this model may parallel human AKI
after aortic surgery or renal transplantation, it greatly exaggerates the degree of tubular injury
compared with that in the limited number of available human renal biopsies and is probably
less relevant to AKI that does not follow hypoperfusion (Heyman et al. (2010)). Even in
this model there is limited understanding of how major pathophysiological events in AKI
are integrated, for example, the mechanism and timing of the switching “off” and “on” of
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glomerular filtration. With few exceptions (Alejandro et al. (1995); Myers et al. (1984)), most
of our experimental interventions have been validated only in this and nephrotoxic animal
models (Vaidya et al. (2010)).
While there is a great deal of information about a large number of cellular (tubular
and endothelial) events and the autonomic, inflammatory and renal vascular responses in
experimental ischemia-reperfusion injury (Devarajan (2006); Heemskerk et al. (2009)), there
is little corroborative and time-relevant clinical pathophysiological data. Usually, the clinical
diagnosis of ischemic AKI is a diagnosis of exclusion. Thus, the potential delay imposed by
reliance on creatinine is further delayed by investigations (eg exclusion of urinary outflow
obstruction) or interventions (fluid loading to treat underlying “pre-renal” AKI) designed
to exclude rather than confirm the diagnosis of ischemic AKI. Other investigations such as
measurement of global or parenchymal renal blood flow, or renal biopsy, which might provide
insight into human AKI, are delayed, difficult to interpret in the absence of baseline data, and
usually not performed.
Since diagnosis is delayed it is not surprising, that there has been failure of pharmacological
intervention in clinical trials, which are largely based on experimental interventions to prevent
rather than treat AKI (Jo et al. (2007)). However, pharmacologic prevention of AKI has also
largely failed, even when the apparent aetiology is known, eg parenteral administration of
iodinated radiocontrast (Fishbane (2008); Nigwekar et al. (2009); Zoungas et al. (2009)). The
failure to translate apparently effective pharmacologic preventive measures in animal models
into clinical practice, suggests that the serum creatinine-inspired delay in diagnosis, merely
complements a lack of fundamental understanding of pathophysiology in human AKI.
2.2 The rise and rise of injury
The change in nomenclature from acute renal failure to acute kidney injury recognised
that an acute decline in renal function is usually secondary to injury (American Society of
Nephrology Renal Research Report (2005); Mehta et al. (2007)). The need for a renal-specific
biomarkers of injury akin to a troponin was presaged in the late 1990s (Star (1998)) and the
discovery of such proteins was later accorded highest priority by The American Society of
Nephrology (American Society of Nephrology Renal Research Report (2005)) with the expectation
that such biomarkers would: “Diagnose AKI before the rise in serum creatinine; Stratify
patients with respect to severity of injury and; Provide prognostic indicators.” The term
“secondary prevention” was introduced to highlight that biomarker detection would lead to
early intervention ideally prior to loss of GFR (Pickering & Endre (2009c)).
Some urinary proteins, notably α1-microglobulin, β1-microglobulin, and
N-acetyl-β-D-glucosaminidase (NAG), were already known to be associated with acute
tubular injury (Yu et al. (1983)), whilst others awaited discovery. In 1998 Kidney Injury
Molecule-1 (KIM-1) was identified as being upregulated in the proximal tubule cells after
ischemic/reperfusion (I/R) injury (Ichimura et al. (1998)) and soon discovered in the urine
of patients with I/R injury (Han et al. (2002)). Around the same time a small study of ICU
patients identified urinary tubular injury makers, α and pi-glutathone S-transferase (α and
pi-GST), and the bursh border enzymes, γ-glutamyl-transpeptidase (GGT) and alkaline
phosphatase (AP), as diagnostic of AKI (Westhuyzen et al. (2003)). A transcriptome wide
interrogation study to identify genes induced early after I/R injury identified neutrophil
gelatinase-associated lipocalin (NGAL) to be upregulated in a mouse model (Mishra et al.
(2003)). Plasma and urinary NGAL quickly showed spectacular success as diagnostic
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markers. The first, a trial of 71 children undergoing cardiopulmonary bypass of whom
20 developed AKI showed urinary and plasma NGAL to increase 10-fold in AKI 2-h post
surgery (Mishra et al. (2005)). Similarly, interluekin-18, IL-18, first identified as being released
into the urine following I/R injury in mice (Melnikov et al. (2001)) was found to appear in
large quantities in the urine of patients with acute tubular necrosis (Parikh et al. (2004)).
Proteomic and genomic approaches continue to be a rich source of new urinary proteins
which may predict AKI (Bennett & Devarajan (2011); Devarajan (2008)).
AKI Biomarker discovery has followed the well trodden path of “early promise” with some
highly sensitive and specific biomarkers in demographically homogeneous populations (eg
paediatric cardiopulmonary bypass surgery), followed by a more tempered response as
studies evaluated candidate biomarkers in demographically heterogeneous populations with
multiple causes of AKI and co-morbidities. There is no one biomarker which will successfully
diagnose or predict a decline in renal function in all situations. Three factors have emerged
which are likely to become determinant factors in the choice of biomarker for a particular
clinical context, namely: (i) likely aetiology of AKI, (ii) pre-existing renal function, (iii) time
from renal insult. IL-18 is an example of a biomarker which has been shown to be elevated
following ischaemic/repurfusion injury (Hall et al. (2010); Parikh et al. (2006)), but possibly
not following radiocontrast induced nephrotoxic injury (Bulent Gul et al. (2008)). Mcilroy
et al demonstrated that in a cohort of 426 adult cardiac surgery patients urinary NGAL
concentrations post-operatively did not differ between those who developed and those who
did not develop AKI when their estimated baseline GFR (eGFR) was less than 60 ml/min,
yet for those with a normal baseline eGFR (90-120 ml/min) NGAL was significantly elevated
in the AKI cohort (Mcilroy et al. (2010)). In our own head to head comparison of 6 urinary
biomarkers (GGT, AP, NGAL, Cystatin C, IL-18, and KIM-1) in 529 adult patients on entry
to an intensive care unit, we demonstrated that the performance of biomarkers is critically
dependent on both baseline renal function and time from renal insult (Endre et al. (2011)).
Peak diagnostic performance at a level that may be considered clinically useful was limited to
patients with eGFR 90-120 ml/min within 12-h of insult for GGT, 6-h for NGAL and from 6 to
12-h for Cystatin C, IL-18 and KIM-1, and to patients with eGFR < 60 ml/min from 12 to 36-h
for GGT, Cystatin C, NGAL and IL-18.
There are many excellent recent reviews of biomarkers of AKI. The pathophysiology of AKI
in relation to potential biomarkers has been reviewed and discussed specifically in relation
to AKI following cardiopulmonary bypass (Haase et al. (2010)), AKI with varying aetiology
(Vaidya et al. (2008)), and AKI involving biomarker mediators of inflammation (Akcay et al.
(2009)). Reviews of biomarker performance specific to nephrotoxic injury (Bonventre et al.
(2010); Ferguson et al. (2008)), septic AKI (Bagshaw et al. (2007)), ischemic injury following
cardiopulmonary bypass (Haase et al. (2010)), acute allograft rejection and ischemic injury
(Alachkar et al. (2010)) as well as broader reviews across aetiologies (Coca et al. (2008);
Edelstein & Faubel (2010); Endre & Westhuyzen (2008); Malyszko (2010)) have been published
within the last 4 years. We have published a more specialist review considering biomarkers
in the early phase of injury (Pickering & Endre (2009c)) and there has been one meta-analysis
of the performance of NGAL (Haase et al. (2009)).
2.3 Paradigm lost and paradigm found
The relationship between clearance (the function paradigm) and injury has, to date, been
studied in humans primarily in sample populations of about 20 to 600 in which a biomarker’s
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ability to diagnose a subsequent rise in a surrogate marker of function (normally creatinine) is
assessed. However, we need to explore the early stages of, and prior to, loss of renal function
in order to understand the relevant pathophysiology of clinical AKI. We can conceptualise
this as an evaluation of the evolution of injury phase which leads to loss of GFR and the
early loss of function phase immediately following a GFR decrease (Figure 1). Detection
and characterisation of this very early phase in man appears essential for progress. This
highlights the need for quantifying the time course of injury biomarkers in relation to change
in GFR and for real-time assessment of renal function. Two promising techniques are under
development. The ambulatory renal monitor (ARM) is a shielded detector which monitors
extracellular excretion of 99mTcDTPA over up to 24 hours following injection and relates this
to GFR (Rabito et al. (2010)). The ratiometric fluorescence approach monitors the plasma
disappearance of both a rapidly filtered and a poorly filtered fluorescent marker introduced
by a single bolus infusion, changes in the ratio of which enable a calculation of GFR (Wang
et al. (2010)). Both techniques allow a rapid (5 to 15 min) measure of GFR. Ideally these or
similar techniques would allow monitoring of kidney function from prior to the time of insult
through the evolution time until change of GFR and beyond.
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Fig. 1. The paradigm of function compared with the paradigm of injury. Following injury the
early injury biomarker is elevated prior to change in function (here, a 65% loss of GFR,
approximately 6 hours post-injury). The later biomarker takes takes longer to be elevated.
Creatinine is only elevated following loss of GFR (following equation 6)
Much of the literature describes a biomarker as “predicting” AKI when it precedes an increase
in plasma creatinine. However, a biomarker is only truly predictive if it precedes a decrease in
GFR. If it is elevated shortly after such a decrease, then it should be described as diagnostic
rather than predictive of AKI even though it may predict the latter increase in plasma
creatinine.
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3. Defining AKIs
In its broadest sense renal failure is simply the rapid loss of renal filtration (ie decrease in
GFR). As discussed, current clinical diagnosis of AKI and evaluation of novel biomarkers of
kidney injury are largely dependent on observation of changes in creatinine as a surrogate for
a change in GFR. An understanding of the kinetics of the relationship between creatinine and
GFR provides a basis for understanding the definitions of AKI and their limitations. Plasma
cystatin C, an alternative to creatinine (Nejat et al. (2010); Westhuyzen (2006)), follows similar
kinetics.
3.1 Creatinine and cystatin C kinetics
Creatinine and cystatin C are generated in tissue outside of the plasma compartment, diffuse
into the plasma compartment from where they are lost by renal and non-renal excretion.
Because both creatinine and cystatin C are not bound to plasma proteins the exchange between
the extravascular and plasma compartments is rapid (compared with rates of production
and elimination) allowing us to conflate the two compartments into one compartment with
volume of distribution, V (Figure 2).
Fig. 2. One compartment pharmacokinetics model
The change in total mass (q) of creatinine/cystatin C depends on the rate at which it is entering
and the rate at which it is leaving the compartment:
dq
dt
= gain from generation− (renal loss + non-renal loss) (1)
Under normal circumstances non-renal losses are much less than renal losses and may be
ignored. The renal loss is the product of the renal elimination rate constant, kr, and the total
mass, q. As the total mass is the product of the concentration C and volume of distribution V,
equation 1 becomes:
C
dV
dt
+
dC
dt
V = G− krCV (2)
where G is the generation rate of creatinine/cystatin C (see Box 3.1). The volume of
distribution of creatinine is equal to the total body water (TBW) and that of cystatin C to
the extracellular fluid (about one third of TBW)(see Box 3.2). If this is assumed not to change
then equation 2 becomes:
dC
dt
=
G
V
− krC (3)
At equilibrium (dC/dt = 0 at t = 0), prior to any change in GFR the renal elimination rate
constant may be determined from equation 3:
kr0 =
G
CbV
(4)
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where Cb is the baseline concentration (at time t = 0). kr0 may also be estimated from the renal
clearance (Cl) which is simply the product kr0 and V. For creatinine, this may be measured
in critically ill paitients using a short duration creatinine clearance and an estimate of an
individual’s volume of distribution (see below). From the EARLYARF study (Endre et al.
(2010)) where 4-h creatinine clearances were measured on entry to ICU in 484 patients we
were able to calculate a median (interquartile range) for kr0 of 0.11 (0.07-0.17) h
-1.
Following a loss in GFR (∆g%), the renal elimination rate constant becomes:
kr = (1−
∆g
100
)kr0 (5)
and equation 3 may be solved numerically, or, if we assume of G, V, or kr are not varying,
may be integrated to give the concentration as a function of time (Chiou & Hsu (1975); Chow
(1985)):
C(t) =
G
krV
(1− e−kr t) + Cbe
−kr t (6)
As t → ∞ the concentration asymptotically approaches a new steady state, Css which from
equation 6 is:
Css =
G
krV
(7)
Mathematically the concentration is within 5% of the new steady state in 4.4 half lives
(Half life: t1/2 = ln(2)/kr). In practice this is well within the uncertainty in creatinine
measurements. The new steady state may also be determined by substituting equations 5
and 4 into equation 7:
Css =
Cb
(1−
∆g
100 )
(8)
From this equation we may determine the equivalences between a decline in GFR and a rise
in creatinine used in the RIFLE definition of AKI (Table 1).
Box 3.1. Creatinine and Cystatin C production rates
Creatinine production (Bjornsson (1979)):
Male (r2 = 0.919): G0 = (27− 0.173× age)× weight/24 (mg/h)
Female (r2 = 0.966): G0 = (25− 0.175× age)× weight/24 (mg/h)
Creatinine production may decrease during critical illness (Griffiths (1996)). If the reduction is at
constant rate m%, (eg 2% per day as suggested by Griffiths) then:
G(t) = G0e
−mt and
dG
dt
= −mG
Cystatin C production
Only one study has measured the rate constant of Cystatin C (Sjostrom et al. (2005)). There was no
significant difference with age, sex or lean body mass. The rate constant per 1.73m2 of body surface
area was:
GCysC = 7.44 (mg/h/1.73m
2)
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Box 3.2. Estimating the volume of distribution
The volume of distribution of creatinine is equal to the total body water (TBW) and of cystatin C to
the volume of the extracellular fluid which is about 1/3rd of the TBW (Hansen (2002)). TBW is often
estimated from the body weight as:
TBW = 0.6× Body weight (L)
More accurate formulae have been derived from population studies (Watson et al. (1980)):
Male (r2 = 0.704): TBW = 2.447− 0.09516× age + 0.1074× height + 0.3662× weight (L)
Female (r2 = 0.736): TBW = 2.097 + 0.1069× height + 0.2466× weight (L)
where height is measured in cm, weight in kg, and age in years.
Where height is not available, the slightly less robust equations may be used:
Male (r2 = 0.689): TBW = 20.03− 0.1183× age + 0.3626× weight (L)
Female (r2 = 0.717): TBW = 14.46 + 0.2549× weight (L)
3.2 Categorical consensus
In 2004 the Acute Dialysis Quality Initiative Group (ADQI) developed a consensus definition
for AKI and severity staging (RIFLE: Risk, Injury, Failure, Loss, End Stage) (Bellomo et al.
(2004)). The scheme involved both a creatinine based classification and a urine output
based classification (Table 1). A decrease in GFR of more than 25% or increase in serum
creatinine of 50% was deemed sufficient to diagnose AKI. Unfortunately, there was an
error in calculating this relationship which was not identified until 2009 (Pickering & Endre
(2009a)). A 50% increase in creatinine is equivalent to a one third decrease in GFR (see
equation 8) not a 25% decrease. Similarly, for RIFLE stage F a 200% increase in creatinine
is equivalent to a two thirds decrease in GFR not a 75% decrease. Whilst plasma creatinine
rather than a GFR measure, or an estimation with creatinine clearance, is the analyte of
choice in AKI studies, creatinine is but a surrogate for GFR and GFR should remain the
principal diagnostic parameter of AKI (Pickering & Endre (2009b)). The ADQI group
recommended AKI be defined as “sustained” (lasting at least 24hrs) and “abrupt” (1-7 days)
(http://www.ccm.upmc.edu/adqi/ADQI2/ADQI2g1.pdf). Whilst duration did not appear
in the seminal RIFLE publication it was included in later publications (Hoste et al. (2006);
Lameire et al. (2006)).
On the back of new evidence that even minor changes in serum creatinine are associated
with poor outcomes (eg Chertow et al. (2005); Lassnigg et al. (2004)), the Acute Kidney Injury
Network modified the RIFLE definition to include a small absolute rise in creatinine (0.3
mg/dl or 26.4 µmol/l). Further modifications included requiring the change to occur within
48 hours for the definition of AKI, and removing RIFLE stages L and E in preference to all
patients requiring renal replacement therapy to be assigned to severity stage III (Table 1).
Both definitions have received broad support and there is considerable evidence for an
association of increased mortality with increased RIFLE or AKIN stages (Bagshaw et al. (2008);
Ricci et al. (2008)). More recently, duration of AKI (using the AKIN criteria) has been shown
to be independently associated with long-term mortality (Brown et al. (2010); Coca et al.
(2010); Goldberg et al. (2009)). KDIGO (Kidney Disease for Improving Global Outcomes:
133he Metamorphosis of Acute Renal Failure to Acute Kidney Injury
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www.kdigo.org ) has recently reviewed the use of the AKIN and RIFLE criteria and is shortly
to release a new consensus definition which combines the two definitions.
RIFLE AKIN RIFLE and AKIN
Stage Creatinine
increase
GFR
decrease
Stage Creatinine
increase
Urine output
Risk (R)  50% > 33.3%∗ I  0.3 mg/dl or
 50%
< 0.5 mg/kg/h
for 6 h
Injury (I)  100% > 50% II  100% < 0.5 mg/kg/h
for 12 h
Failure (F)  200% or
 0.5 mg/dl and
above 4.0 mg/dl
> 66.7%∗∗ III  200% or
 0.5 mg/dl and
above 4.0 mg/dl
< 0.3 mg/kg/h
for 24 h or
anuria for 12 h
*,** corrected from 25% and 75% see Pickering & Endre (2009a)
Table 1. Severity Staging: Consensus definitions
3.3 A continuum needing continuous variables
One of the intentions of ADQI in setting up RIFLE was that it would provide common
outcomes in clinical trials. During the four year period (2005-08) only 36% of published
AKI (non Contrast Induced Nephropathy, CIN) trials used RIFLE or AKIN as an outcome
variable, and the use was not consistent in terms of timing and duration of injury (Endre &
Pickering (2010)). Amongst CIN intervention trials only 13% used RIFLE or AKIN, whereas
most continued to use an increase in creatinine of  25% and/or  0.5 mg/dl (44.2 µmol/l)
to diagnose CIN. This later definition is slightly anomalous as only those with pre-existing
kidney disease (creatinine > 2.0 mg/dl) can have a greater than 0.5 mg/dl elevation in
creatinine that is less than 25%. We have recommended that all CIN studies adopt the AKIN
or RIFLE definition of AKI (Endre & Pickering (2010)).
We investigated whether a continuous variable measure of kidney function, the Relative
Average Creatinine (RAVC), performed better than the RIFLE and AKIN categorical
definitions as an outcome variable in AKI prevention or intervention trials. The RAVC is
the integral of the area under the plasma creatinine curve above baseline creatine divided by
the total time and baseline creatinine:
RAVC(%) =
100
Cbt
∫ t
0
(C(t)− Cb)dt (9)
which in practice is calculated using the trapezoidal rule (Figure 3):
RAVC(%) =
100
Cb(tN − t1)
∑
0<n<N−1
(Cn+1 − Cb) + (Cn − Cb)
2
(tn+1 − tn) (10)
where N is the number of creatinine measurements.
We created a population of 10,000 Virtual-In-Patients (VIPs) whose baseline creatinine and
changes in GFR were based on real ICU populations. Placebo controlled trials were
simulated by randomly assigning half the VIPs to treatments which ameliorated loss of renal
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Fig. 3. The Relative Average Creatinine by the trapezoidal rule is the sum of the areas A to E
divided by (t6 − t1)(following equation 10).
function (ie reduced the reduction in GFR). The more efficacious the treatment, the less the
decrease in GFR. Creatinine profiles were calculated using equation 6 (Pickering et al. (2009)).
AKIN, RIFLE and RAVC as outcome variables were compared. At low treatment efficacy,
the categorical outcomes underestimated and at high treatment efficacy overestimated the
effect of treatment. These effects were exaggerated when the population contained a high
proportion of patients with more severe AKI. The RAVC, on the other hand, responded
in an almost linear fashion across treatment efficacies. Importantly, when the efficacy was
low it was best able to distinguish between placebo and treatment arms. The advantage
of the RAVC over the categorial metrics is two fold, first it includes the effect of treatment
on those patients who had mild kidney injury which in normal circumstances would not
exceed the diagnostic threshold for AKI according to a categorical definition, but which may
result in a small increase (eg 20-30%) in creatinine and, second, it measures function over
a (pre-determined) time period. As discussed previously, the length of time creatinine is
elevated is independently of the maximum elevation associated with mortality. The RAVC
captures both severity and duration of injury and was used as the primary outcome in the
EARLYARF trial, which was the first randomised control trial to use an injury biomarker to
triage patients to placebo or high-dose erythropoietin (Endre et al. (2010)).
3.4 The baseline issue
All creatinine based definitions of AKI and the RAVC depend on knowing the normal, or
“baseline”, plasma creatinine for each individual. For patients undergoing elective surgery
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this is easily obtainable prior to surgery. However, about half of the patients entering the
ICU have no previous record of plasma creatinine to serve as a baseline. For trials this
requires a retrospective determination of renal function. The ADQI recommend assuming a
normal (eg 75 ml/min) GFR for all these patients and “back-calculating” a plasma creatinine
using the MDRD equation. Unfortunately, this has proved erroneous. We showed that in
our VIP population and in an ICU population that this approach seriously overestimates the
proportion of patients with AKI using either the AKIN or RIFLE definitions (Pickering &
Endre (2010); Pickering et al. (2009)). Randomly assigning a baseline creatinine produced
just as accurate results as back-calculation. In a population already with AKI the presence of
patients with CKD was seen to be driving the overestimation (Bagshaw et al. (2009)). Using
the emergency department creatinine as an alternative baseline underestimated AKI (AKIN)
and lowered the sensitivity (Siew et al. (2010)).
In the EARLYARF trial we overcame this problem by using an adjudicated hierarchical
approach to choose in each patient the measured plasma creatinine that best represented
normal renal function. Outpatient plasma creatinine prior to admission were considered the
most likely to represent true baseline function. Whilst CKD can be diagnosed over three
months, up to twelve months appears to be a reasonable time period prior to admission in
which to ascertain baseline creatinine as it reduces misclassification of AKI (Lafrance & Miller
(2010)). Amongst patients with no pre-admission creatinine measurement, a post-discharge
measurement is the next best option if it is stable. Increasing creatinine may be indicative
of developing CKD. Hence, it is preferable that a post-discharge creatinine is within three
months of the insult. As a last resort the lower of the first hospital or final hospital (when
there is recovery) may be used. We have presented our recommended hierarchical approach
in table 2. This differs from the earlier approach in that we now consider that for cardiac arrest
and trauma patients where there is no baseline prior to admission available the first hospital
sample is likely to be the best estimate of baseline function if it is measured close to the time of
renal insult. In our experience this is less than 2-h for most cardiac arrest and trauma patients.
For the creatinine to have increased considerably in this time frame the loss of GFR would
have had to have been substantial.
3.5 Quantifying function in a dilute environment
Fluid resuscitation dilutes plasma creatinine concentrations, which in turn may lead to
delayed diagnosis or severity underestimation. This may explain why the only successful
AKI intervention in the ICU has been early consultation with a nephrologist (Mehta et al.
(2002)). The effect of fluids may be estimated by adjusting plasma creatinine for fluid balance
(Macedo et al. (2010)):
Cadjusted = Cmeasured ×
admission weight (kg)× 0.6 + ∑ daily cumulative fluid balance (L)
admission weight (kg)× 0.6
(11)
3.6 Injury meets function
Current evaluation of novel biomarkers of renal injury is largely confined to evaluation of
their performance to predict increases in plasma creatinine which lead to a diagnosis of AKI
according to RIFLE or AKIN. This runs the risk of missing significant injury because creatinine
did not increase beyond the diagnostic threshold of 50% or 0.3 mg/dl. In a large series
36 Basic Nephrology and Acute Kidne  Injury
www.intechopen.com
The Metamorphosis of Acute Renal Failure to Acute Kidney Injury 13
Situation Timing of baseline creatinine sample
1 Elective surgery Prior to surgery
2 All Pre-hospital outpatient or prior admission
Preferably this is between 7 and 90 days prior to admission. 7 days avoids
a period which may reflect changing renal function. Less than 90 days is
preferable because 90 days is the period usually used to diagnose CKD.
Up to 365 days may be used if there is little likelihood of CKD having
developed during that period.
3 Cardiac Arrest First hospital
If a pre-hospital value is not available and the time between insult and the
first measurement is short (< 2h). Within a short time frame the creatinine
will not (yet) have become elevated.
4 Trauma First hospital
If a pre-hospital value is not available and the time between insult and the
first measurement is short (< 2h) and crush-injuries are not involved.
5 Post ICU discharge
Within 90 days of admission to avoid capturing the development of CKD.
6 Lowest of first hospital or final ICU
Table 2. Hierarchical determination of baseline creatinine
of experimental studies of nephrotoxic AKI biomarkers, serum creatinine and blood urea
nitrogen (BUN) were the poorest predictors of histologically determined injury compared
with numerous urinary biomarkers (Dieterle et al. (2010); Ozer et al. (2010); Vaidya et al.
(2010); Yu et al. (2010)). In what may turn out to be a seminal publication Haase et al. (2011)
demonstrated that across 10 studies patients with a positive NGAL, yet negative plasma
creatinine, for AKI had worse outcomes (mortality, need for dialysis, and ICU length of stay)
than those with both negative NGAL and negative creatinine.
Biomarker clinical utility is most often quantified by the area under the receiver operator
characteristic curve (AUC or c-statistic, see Box 3.3). The AUC is crude estimation of the
ability of the biomarker to distinguish between those with and without AKI. However, a high
AUC does not necessarily imply clinical utility. Clinical utility depends on what alternative
biomarkers there are, what treatments are available, and the risks and costs involved with
false negatives or false positives. The calculation of the sensitivity, specificity and particularly
the negative and positive predictive values at either an established cut-off from the literature,
or a cut-off chosen for clinical reasons, or derived mathematically from the ROC. The latter is
usually either the cut-off closest to a Sensitivity and Specificity of 1 or the Youden index.
Comparing AUCs between different studies is problematical. AUCs for AKI are highly
dependent on the AKI definition. Typically a definition requiring greater injury (eg RIFLE
sustained for 24-h, compared with an increase of 0.3 mg/dl within 48-h) will result in higher
AUCs. Within a study when more than one biomarker is being measured they should be
compared using the method of DeLong (DeLong et al. (1988)). One biomarker should not
be described as “better” than another unless the difference between the two is statistically
significant at p < 0.05.
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Box 3.3. The Area Under the Curve (AUC)
The receiver operator characteristic curve (ROC) is a plot of sensitivity verse 1-specificity. An AUC of
1 means the biomarker always discriminates between patients with and without the disease (no false
negatives and no false positives). An AUC of 0.5 is equivalent to a coin toss. Whilst an AUC of less
than 0.5 means the reciprocal of the biomarker is diagnostic. Some statistics packages, however, will
always express the AUC as greater than 0.5 by inverting the biomarker concentration where necessary.
The AUC from a study is strictly speaking an estimate of the AUC of the population, therefore it should
always be presented with appropriate confidence intervals (usually 95%). The 95% confidence interval
is ±1.96 times the standard error of a proportion:
ÂUC− 1.96
√
ÂUC(1− ÂUC)/n to ÂUC + 1.96
√
ÂUC(1− ÂUC)/n
where n is the sample size and ÂUC the estimated AUC. This is equation is adequate for sample sizes
> 30, but for smaller sample sizes a bootstrapping should be used. Only an AUC for which the lower
limit of its 95% confidence interval is greater than 0.5 may be described as diagnostic (or prognistic).
Figure 4 is an example of a ROC from the EARLYARF trial (Endre et al. (2011)). It shows the ability of
NGAL to diagnose AKI when the sample was taken between 12 and 36 hours following renal insult.
The AUC lower limit of the 95% confidence interval, 0.62, is greater than 0.5, therefore it is diagnostic.
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Fig. 4. An example of a receiver operator characteristic curve
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It is anticipated that panels of biomarkers will be needed to diagnose AKI in heterogeneous
populations with multiple AKI aetiologies. Attempts to assess a panel of biomarkers usually
involve logistic regression models with two or more biomarkers measured at the same time
point. The EARLYARF trial has demonstrated that the efficacy of any one particular biomarker
is very much time dependent, and that each biomarker has its own “window of opportunity”
during which it has have diagnostic utility (Endre et al. (2011)). Logistic regression models are
not a suitable approach for assessment of biomarker panels because of this. Until we know the
time courses of biomarkers much better, an “either and/or” approach is likely to yield greater
results. For example, in an ICU population either an elevated GGT and/or an elevated NGAL
may be considered diagnostic.
There is a need to move away from assessing injury biomarkers only in relation to function.
All trials should report mortality data, even if the incidence is too low for statistical analysis.
This will facilitate later meta-analysis of the relationship between a biomarker and mortality.
The EARLYARF trial paved the way for future trials of early intervention based on an elevated
biomarker. Since the inception of that trial new biomarkers with rapid assay turn-around
(necessary in an early intervention trial) have become available. Plasma and urinary NGAL,
and KIM-1 head the list along with urinary Cystatin C and GGT which are already routinely
available in many hospital laboratories. It is anticipated that the next early intervention trial
will use one or more of these biomarkers.
3.7 Quantifying injury in a dilute environment
Changes in GFR and water handling will change urinary biomarker concentrations
independent of injury. Normalising biomarkers to urinary creatinine has been proposed to
account for these effects. This process also amplifies the signal soon after a decline in function
(Waikar et al. (2010)). This may be advantageous in an early intervention trial if the threshold
for intervention is set high enough, but it may distort the analysis of biomarker performance in
a biomarker performance study. Whilst there is no consensus on whether biomarkers should
or should not be normalised to urinary creatinine we recommend reporting both normalised
and non-normalised results.
4. Practical considerations
Table 3 presents a summary of practical measures to take into account when planning AKI
epidemiology, biomarker efficacy studies or prevention or intervention trials.
4.1 Epidemiology
Most epidemiological studies are retrospective and face the difficulty of missing data,
particularly baseline creatinine data. This was discussed in section 3.4. It is important to
quantify the severity of AKI, as more severe AKI is likely to have greater long term impact
on health resources. Where possible, data on the duration of AKI as well as severity should
be captured as this is an independent predictor of outcome. Three areas of epidemiology lack
data. First, there are comparatively few good epidemiology studies in countries other than in
Europe, North America or Australasia (Cerda et al. (2008)). The incidence of AKI in countries
with large populations such as China, India, Indonesia, Nigeria has significance beyond their
own borders. Some countries have numbers of particular AKI aetiologies which, if well
studied, could provide useful data world-wide. For example, with anti-retroviral therapy
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reducing mortality in HIV patients, the incidence of AKI in this population may be increasing
(Lopes et al. (2011)). In South-East Asia, AKI is a prominent complication of paraquat (a
contact herbicide) self-poisoning (Roberts et al. (2011)). In both these cases epidemiology in
countries with relevant populations would help identify the extent of risk in other countries
where incidence of HIV or paraquat poisoning is relatively low. Second, there are few studies
that have investigated AKI on CKD (Ali et al. (2007)). The growing world wide epidemic
of CKD demands epidemiology that quantifies the additional risk CKD has for AKI and the
effects of AKI on the progression of CKD. Third, there are few studies on CKD induced by AKI
that have comparable control groups of hospitalised non-AKI patients (Coca et al. (2009)).
4.2 Biomarker studies
It is important to report the timing of sampling for biomarker measurements in relation to
putative onset of injury. As we have seen, different biomarkers are likely to have different
time profiles. A weakness of many studies is that samples are taken only at one or two time
points, and even then they may be outside the temporal “window of opportunity” of the
biomarker, possibly rendering the study results misleading. Temporal profiles are available
for many biomarkers following the time of injury which can be used to plan sampling (eg
Endre et al. (2011)) . For novel biomarkers, frequent sampling will be necessary to establish
their time course. The first 12 hours following injury are crucial as this is the window for early
intervention. There is also a need to discover and assess injury biomarkers with slightly longer
(∼24 to 36-h) time courses as samples may not be able to be taken earlier in many critically ill
patients. Very few studies have measured biomarker profiles beyond a two or three days, yet
there is tantilising evidence that some biomarkers (eg KIM-1) may become elevated during a
repair phase which in some patients may not begin until several days following injury.
The choice of outcome variable is particularly important. Despite the caveats discussed
with respect to using creatinine changes as a surrogate for change in GFR and the issue of
comparing injury to function, we are still in a period where a functional definition of AKI is
likely to be the outcome of choice for biomarker studies. Use of non-standard AKI definitions
are unhelpful and should be avoided in preference to the AKIN, RIFLE and, potentially, new
KDIGO AKI definitions. The duration as well as severity of creatinine increase is also of
importance. The AKIN definition requires only one time point at which plasma creatinine
may be elevated. This allows for mild and transient changes in function to equally be
recorded as AKI. We have shown that transient increases in creatinine are associated with
injury biomarkers (Nejat et al (2011b)), although not to the extent of more sustained increases.
We recommend evaluating biomarkers in relation to duration of increase of creatinine as well
as the increase itself.
Most biomarker studies are underpowered. The number of participants are rarely calculated
a priori. Typically we want to ascertain if a biomarker is clinically useful. At a minimum
we would want an AUC of 0.7, more likely 0.85 or greater. Given an expected incidence
(proportion), I, in the population, how many participants (N) will we need in the study?
Hanley and McNeil provide a general equation which we may adapt as we are interested in
the difference between the true AUC and 0.5 (Hanley & McNeil (1982)):
N =
1
I
[
0.5773Zα + Zβ
√
0.1667 + AUC2−AUC +
2AUC2
1+AUC − 2AUC
2
AUC− 0.5
]2
(12)
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where Zα is the Z coefficient for a Type I error and Zβ for a Type II error. In order to detect
a true AUC of 0.7 with p<0.05 (Zα = 1.96 (two sided)) and at 80% power (Zβ = 0.84) in
a population with a 30% incidence 212 participants would be needed. A population with a
much lower incidence, say 5%, would need a much greater sample (N = 1269). If we were
comparing a known biomarker with an AUC of 0.7 and wanting to know if another biomarker
was better (AUC of 0.8 or more), then at p<0.05, 80% power and 30% incidence we would need
676 participants. This highlights the importance of knowing a priori the AKI incidence, what
a clinically relevant AUC would be, and choosing a sample size appropriately.
In larger studies it is possible to assess the biomarker’s ability to predict premature death or
need for renal replacement therapy. In both cases, it is important to assess the risk relative
to known risk factors. A useful technique is to use logistic regression models and compare
a model of known risk factors with one with the same risk factors plus the biomarker. The
integrated discrimination improvement (IDI) is a useful technique which, along with the
AUC, allows for analysis of biomarker performance across the whole range of biomarker
concentrations (Pencina et al. (2008)).
Studies in heterogeneous populations with multiple aetiologies and timing of injury are
particularly difficult. Given the recent findings with respect to biomarker dependency on
pre-existing renal function it is important that study size is sufficient to allow for cohort
analysis, in particular cohorts of CKD and sepsis. In studies with CKD patients it is important
to measure urinary albumin. Albumin is a possible AKI biomarker in its own right, but
also competes for reabsorption in the proximal tubules with cystatin C and NGAL, IL-18 and
possibly other markers (Nejat et al (2011a)).
The quality of reporting of biomarker studies varies widely. The Standards of Reporting of
Diagnostic Accuracy (STARD) statement provides minimum standards and is worth referring
to in the planning of the study (Bossuyt et al. (2003)). Biomarker concentrations should almost
always be presented as median with inter-quartile range as they are usually non-normal
distributions. With the jury still out on “normalising” urinary biomarkers to urinary creatinine
we have recommended that both normalised and non-normalised results be presented.
4.3 Clinical trials
Clinical trial design follows one of three paradigms: (i) Prevention, namely treatment prior
to a procedure which may cause injury; (ii) Early intervention following following a raised
biomarker, but prior to observation of functional change (eg Endre et al. (2010)); (iii) Late
intervention following an elevation of creatinine (Pickering & Endre (2009c); Pickering et al.
(2011)). Whilst it may be anticipated that if successful prevention or early intervention
treatments are developed there will be less need for late intervention treatments, late
intervention treatments will still be needed either where prevention or early intervention
fails, or where it is not possible to administer it. Injury biomarkers will play a role in all
three paradigms. Some are being identified as risk factors, prior to a procedure (Bennett et al.
(2008)), whilst others will be elevated early enough after injury to allow early intervention,
finally others will serve as outcome variables. As with plasma creatinine as an outcome
variable, analogous to the RAVC, it is likely that a continuous measurement of the biomarker
over a pre-specified duration will serve best as an outcome variable.
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Epidemiology
Biomarker
Studies
Clinical
Trials
1 Use a continuous outcome variable (eg RAVC) n/a possibly ✔
2 Use RIFLE, AKIN or KDIGO definition as
outcome variables (including for CIN trials)
✔ ✔ ✔
3 Use a hierarchical-adjudicated approach to
determine baseline creatinine
✔ ✔ ✔
4 Include hard outcomes (RRT, Death) ✔ ✔ ✔
5 Include plasma cystatin C as an outcome n/a ✔ ✔
6 For subcohort analysis use KDIGO
guidelines for CKD staging (Levey
et al. (2003))
✔ ✔ ✔
7 Measure 2 to 4-h creatinine clearance n/a ✔ ✔
8 Use corrected ∆GFR(%) for RIFLE classes R or F
(Pickering & Endre (2009a))
n/a ✔ ✔
8 Apply treatment within the time window
following insult determined by experimental
&/or pilot data
n/a n/a ✔
9 Measure biomarkers within the time window
following insult determined by experimental
&/or pilot data
n/a ✔ n/a
10 Report urinary biomarker concentrations &
concentrations normalised to urinary creatinine
n/a ✔ n/a
11 Report median and inter-quartile range for
biomarker concentrations
n/a ✔ n/a
12 Report times and duration for which plasma
outcomes were determined
✔ ✔ ✔
Table 3. Practical considerations
5. Conclusion
The discovery of many early biomarkers of kidney injury has begun to shift the paradigm from
assessment of change in filtration function to measurement of direct injury. Lest we throw the
baby out with the bathwater we must recognise the complementary role of assessing both
renal injury and renal function. Our techniques for assessing injury are still in their infancy,
but show much promise. Our techniques for assessing function have a long history, yet, as we
have shown, have room for improvement. In particular, we are learning to use appropriate
surrogates of function, categorical or continuous, depending on the type of study we are
conducting. We await the development of rapid, near “real-time” measures of function which
are the missing link in enabling us to understand the temporal profile of injury in relation to
functional change. We also look forward to an era of clinical trials which utilise the injury
biomarkers discovered to date so as to properly test of drugs found to be effective soon after
injury in experimental models.
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